Zobrazeno 1 - 10
of 79
pro vyhledávání: ''
Autor:
Jacalyn Rosenblatt, Diane Warren, Kelly Masone, Dena Grayson, Sascha A. Tuchman, Kathleen Colson, Paul G. Richardson, Jacob P. Laubach, Robert A. Redd, Constantine S. Mitsiades
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 2, Pp 1-8 (2021)
Blood Cancer Journal
Blood Cancer Journal
Additional therapeutic options are needed for relapsed and refractory multiple myeloma (RRMM). We present data from a phase 1b, open-label, dose-escalation study (NCT01965353) of 20 patients with RRMM (median age: 63 years [range: 50–77]) and a med
Autor:
Cecilie L. Bager, M. H. Tang, Anne-Christine Bay-Jensen, Søren Brunak, P. Frederiksen, Morten A. Karsdal, Joseph P.M. Blair
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-9 (2020)
Scientific Reports
Blair, J P M, Bay-Jensen, A-C, Tang, M H, Frederiksen, P, Bager, C, Karsdal, M & Brunak, S 2020, ' Identification of heterogenous treatment response trajectories to anti-IL6 receptor treatment in rheumatoid arthritis ', Scientific Reports, vol. 10, no. 1, 13975 . https://doi.org/10.1038/s41598-020-70942-x
Scientific Reports
Blair, J P M, Bay-Jensen, A-C, Tang, M H, Frederiksen, P, Bager, C, Karsdal, M & Brunak, S 2020, ' Identification of heterogenous treatment response trajectories to anti-IL6 receptor treatment in rheumatoid arthritis ', Scientific Reports, vol. 10, no. 1, 13975 . https://doi.org/10.1038/s41598-020-70942-x
Rheumatoid arthritis (RA) is a chronic inflammatory disease with fluctuating course of progression. Despite substantial improvement in treatments in recent years, treatment response is still not guaranteed. The aim of this study was to identify varia
Autor:
Binghe Xu, Wei Li, Yeon Hee Park, W. Wu, Quchang Ouyang, Mark E. Robson, Seock-Ah Im, Ling Ming Tseng, Dah Cherng Yeh, C. Goessl, Joohyuk Sohn, Norikazu Masuda, Hiroji Iwata
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-8 (2020)
Scientific Reports
Scientific Reports
The OlympiAD Phase III study (NCT02000622) established the clinical benefits of olaparib tablet monotherapy (300 mg twice daily) over chemotherapy treatment of physician’s choice (TPC) in patients with a germline BRCA1/2 mutation (gBRCAm) and human
Autor:
Asbjørn Svardal, Rita Skårdal, Johannes R. Hov, Pål Aukrust, Beate Vestad, Arne Yndestad, Lars Aaberge, Christopher Storm-Larsen, Thor Ueland, Ingebjørg Seljeflot, Tom H. Karlsen, Rolf K. Berge, Lars Gullestad, Asgrimur Ragnarsson, Ole Geir Solberg, Martin Kummen, Marius Trøseid, Kristian Holm
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-9 (2020)
Scientific Reports
Scientific Reports
The gut microbiome contributes to the variation of blood lipid levels, and secondary bile acids are associated with the effect of statins. Yet, our knowledge of how statins, one of our most common drug groups, affect the human microbiome is scarce. W
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-8 (2020)
Scientific Reports
Scientific Reports
The recommended antiviral drugs available for the treatment and prevention of influenza are neuraminidase inhibitors (NAIs). The aim of this study was to evaluate age-related clinical manifestations of adverse events (AEs) related to NAIs. FAERS and
Autor:
Ulrich Bothner, Kristina Laugesen, Jetty A. Overbeek, Vera Ehrenstein, Jaume Aguado, Laura Wallace, E. Houben, Jukka Montonen, Cristina Rebordosa, Joelle Asmar, Alicia Gilsenan
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-9 (2020)
Scientific Reports
Rebordosa, C, Houben, E, Laugesen, K, Bothner, U, Montonen, J, Aguado, J, Overbeek, J A, Ehrenstein, V, Asmar, J, Wallace, L & Gilsenan, A W 2020, ' No Evidence of Off-label Use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands : A Drug Utilization Study ', Scientific Reports, vol. 10, no. 1, 586 . https://doi.org/10.1038/s41598-019-57397-5
Scientific Reports
Rebordosa, C, Houben, E, Laugesen, K, Bothner, U, Montonen, J, Aguado, J, Overbeek, J A, Ehrenstein, V, Asmar, J, Wallace, L & Gilsenan, A W 2020, ' No Evidence of Off-label Use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands : A Drug Utilization Study ', Scientific Reports, vol. 10, no. 1, 586 . https://doi.org/10.1038/s41598-019-57397-5
To characterize the use of olodaterol and indacaterol in clinical practice and to quantify the off-label use in asthma. Drug utilization study of new users of olodaterol or indacaterol between 2014 and 2017 in the PHARMO Database Network in the Nethe
Autor:
Hans Petter Brodal, Hanne E. Puntervoll, Leonardo A. Meza-Zepeda, Lars Birger Aasheim, Bjørn Tore Gjertsen, Rakel Brendsdal Forthun, Randi Hovland, Stian Knappskog, Oddbjørn Straume, Cornelia Schuster, Heidi M. Namløs
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-15 (2019)
Scientific Reports
Scientific Reports
Bevacizumab is included in an increasing number of clinical trials. To find biomarkers to predict and monitor treatment response, cancer and angiogenesis relevant mutations in tumour and circulating tumour DNA (ctDNA) were investigated in 26 metastat
Autor:
Vicente Vicente, María Isabel Orts, Maria Luisa Lozano, Nuria Bermejo, María Perera, Estefanía Bolaños, Luis F. Casado-Montero, Gonzalo Carreño-Tarragona, Elisa Orna-Montero, Manuel A. Rodríguez-López, Isidro Jarque, Tomás José González-López, David Valcárcel, Maria Eva Mingot-Castellano, Aurora de Andrés, Silvana Novelli, Rosa M. Campos-Alvarez, María Fernanda López-Fernández, María Teresa Álvarez-Román, Nuria Revilla, José Ramón González-Porras
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-9 (2019)
Scientific Reports
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
SCIENTIFIC REPORTS
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Scientia
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
r-FISABIO. Repositorio Institucional de Producción Científica
Recercat. Dipósit de la Recerca de Catalunya
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Scientific Reports
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
SCIENTIFIC REPORTS
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Scientia
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
r-FISABIO. Repositorio Institucional de Producción Científica
Recercat. Dipósit de la Recerca de Catalunya
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Very few data exist on when a particular thrombopoietin-receptor agonist (TPO-RA) is favored in clinical practice for the treatment of patients with immune thrombocytopenia (ITP), about novel risk factors for vascular events (VE) with these drugs, no
Autor:
Lynda C. Doward, David Leather, Diane Whalley, Henrik Svedsater, Rebecca Crawford, Nick Bosanquet, James Lay-Flurrie
Publikováno v:
npj Primary Care Respiratory Medicine, Vol 29, Iss 1, Pp 1-9 (2019)
NPJ Primary Care Respiratory Medicine
NPJ Primary Care Respiratory Medicine
The Salford Lung Study in Asthma (SLS Asthma) was a multicentre, randomised, controlled, open-label trial that assessed initiating once-daily, single-inhaler fluticasone furoate/vilanterol (FF/VI) 100 μg/25 μg or 200 μg/25 μg versus continuing us
Autor:
Soo Wan Kim, Su Ah Sung, Curie Ahn, Kook Hwan Oh, Yong-Soo Kim, Tae Ryom Oh, Hong Sang Choi, Eun Hui Bae, Chang Seong Kim, Seong Kwon Ma
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-9 (2019)
Scientific Reports
Scientific Reports
The prevalence of hyperuricemia and chronic kidney disease (CKD) has been steadily increasing. The role of hyperuricemia and efficacy of uric acid-lowering agents against CKD progression remain controversial. This study aimed to evaluate the effect o